RNA (Atrium Therapeutics) ROE % Adjusted to Book Value: -30.77% (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.80
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics ROE % Adjusted to Book Value?

Atrium Therapeutics RNA +0.16% 12 ROE % Adjusted to Book Value is -30.77% as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -30.15%. Atrium Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 0.98. Atrium Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -30.77%.

Atrium Therapeutics ROE % Adjusted to Book Value Related Terms

Atrium Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics ROE % Adjusted to Book Value Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -30.77

RNA vs RNAC, KROS, ARCT: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Atrium Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's ROE % Adjusted to Book Value falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics ROE % Adjusted to Book Value Calculation

Atrium Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-104.92% / N/A
=N/A

Atrium Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-30.15% / 0.98
=-30.77%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -30.77% mean?
Atrium Therapeutics (RNA) has a ROE % Adjusted to Book Value of -30.77% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' ROE % Adjusted to Book Value too high?
Atrium Therapeutics' current ROE % Adjusted to Book Value is -30.77%. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' ROE % Adjusted to Book Value compare to RNAC and KROS?
Atrium Therapeutics' ROE % Adjusted to Book Value of -30.77% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current ROE % Adjusted to Book Value is -30.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current ROE % Adjusted to Book Value of -30.77%. The current ROE % Adjusted to Book Value is -30.77%. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current ROE % Adjusted to Book Value is -30.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.80
Price